why choose us

First received: August 22, 2022

Clinical Trial: Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

Study Status: Completed

Recruit Status: Completed

Condition: Psoriasis

Study Type: Observational


Official Title: Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis in a Real World Setting in the US (Bionaive Secukinumab Users NVS 521)

Brief Summary: The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).

Read more